4//SEC Filing
Fitzgerald Thomas A 4
Accession 0001104659-22-011083
CIK 0001829635other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 6:04 AM ET
Size
5.7 KB
Accession
0001104659-22-011083
Insider Transaction Report
Form 4
Fitzgerald Thomas A
DirectorVP, Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-01+33,000→ 33,000 totalExercise: $2.45Exp: 2031-01-31→ Common Stock (33,000 underlying)
Footnotes (1)
- [F1]Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.
Documents
Issuer
Transcode Therapeutics, Inc.
CIK 0001829635
Entity typeother
Related Parties
1- filerCIK 0001854168
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 6:04 AM ET
- Size
- 5.7 KB